capromab pendetide (Prostascint) Report issue

Biologics mAb Imaging Approved FDA
AACT ChEMBL DrugBank Drugs@FDA MeSH

Active Ingredient History

NOW
  • Now
Indium (111In) capromab pendetide is used to image the extent of prostate cancer. Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single-photon emission computed tomography (SPECT).   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Imaging: 111-indium
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

(111in)-capromab pendetide | 111in-capromab pendetide | 7e11-c5.3 | capromab pendetide | cc49 antibody | cyt-351 | cyt 356 | cyt-356 | cytogen 356 | (iii)in-cyt-356 | indium 111 capromab pendetide | indium-111-cyt-356 | indium (111in) capromab pendetide | indium in 111 capromab pendetide | prostascinct | prostascint

Organizations (12)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Prostatic Neoplasms (approved 1996)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue